

ESMO PRECEPTORSHIP

MUNICH GERMANY 26-27 JULY 2024

Co-Chairs

Alessandra Gennari, Italy Nadia Harbeck, Germany



ESMO PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Munich, Germany 26-27 July 2024

CO-CHAIRS

Alessandra Gennari, Italy Nadia Harbeck, Germany

SPEAKERS

Maria João Cardoso, Portugal Tanja Gagliardi, United Kingdom Valentina Guarneri, Italy David Krug, Germany Joana Mourato Ribeiro, France Daniela Paepke, Switzerland Frédérique Penault-Llorca, France Rachel Wuerstlein, Germany

LEARNING OBJECTIVES

- To enable the interdisciplinary discussion and collaboration in the care of patients with breast cancer
- To understand subtype-specific breast cancer management
- To improve the understanding of current radiological and pathological diagnostics
- To learn about the latest developments in neoadjuvant and adjuvant therapies
- To gain insight into the role of complementary and lifestyle interventions and supportive care
- To review approaches to the care of patients with advanced breast cancer
- To learn about specific needs of young patients with breast cancer

ACCREDITATION

The programme of this event has been accredited with 11 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from







ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4, 6900 Lugano, Switzerland

Email: courses@esmo.org

www.esmo.org



Friday, 26 July 2024

09:00-09:05 5'	Opening remarks	Alessandra Gennari, IT Nadia Harbeck, DE
09:05-11:05	SESSION 1	Chair:
120'	Breast imaging and loco-regional treatment in EBC	Alessandra Gennari, IT
20'	Update on breast radiology	Tanja Gagliardi, UK
10'	Q&A	All
20'	Contemporary breast and axillary surgery	Maria João Cardoso, PT
10'	Q&A	All
20'	Contemporary indications for radiation therapy	David Krug, DE
10'	Q&A	All
20'	Young women: Genetics, counselling and therapeutic consequences	Valentina Guarneri, IT
10'	Q&A	All
11:05-11:35	Coffee break	
11:35-13:10	SESSION 2	Chair:
95'	Systemic therapy in EBC	Nadia Harbeck, DE
25'	Luminal	Nadia Harbeck, DE
10'	Q&A	All
20'	Triple negative	Joana Mourato Ribeiro, FR
10'	Q&A	All
20'	HER2 positive	Rachel Wuerstlein, DE
10'	Q&A	All
13:10-14:10	Lunch	
14:10-15:50	SESSION 3	Chair:
100'	Special situations	Alessandra Gennari, IT
20'	Young women: Special issues (pregnancy, fertility, etc.)	Valentina Guarneri, IT
10'	Q&A	All
30'	Lifestyle, complementary and alternative medicine	Daniela Paepke, CH
10'	Q&A	All
20'	Update on breast pathology: What do we need to know in the clinic? (e.g. liquid biopsy, molecular tumour board)	Frédérique Penault-Llorca, FR
10'	Q&A	All
15:50-16:20	Coffee break	
16:20-18:05	SESSION 4	Chair:
105'	Participants clinical case discussion	Nadia Harbeck, DE
105'	Participants clinical case discussion (7x15')	Faculty
20:00	Dinner	

Saturday, 27 July 2024

13:45-14:45 Lunch

09:00-10:45 105'	SESSION 5 Participants clinical case discussion	Chair: Alessandra Gennari, IT
105'	Participants clinical case discussion (7x15')	Faculty
10:45-11:25 40'	SESSION 6 Loco-regional treatment in MBC	Chair: Alessandra Gennari, IT
30'	Loco-regional therapies in advanced breast cancer - Surgery - Radiotherapy	Maria João Cardoso, PT David Krug, DE
10'	A&Q	All
11:25-11:55	Coffee break	
11:55-13:35 100' 30' 10' 20' 10' 20' 10'	SESSION 7 Systemic therapy in MBC Advanced luminal breast cancer (incl. HER2-low) Q&A Advanced triple negative breast cancer Q&A Advanced HER2 positive breast cancer	Chair: Nadia Harbeck, DE Alessandra Gennari, IT All Joana Mourato Ribeiro, FR All Rachel Wuerstlein, DE All
13:35-13:45 10'	Closing remarks	Alessandra Gennari, IT Nadia Harbeck, DE

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion